JAZZ Maintained by UBS -- Price Target Raised to $337

gurufocus.com · 2026-09-11

Jazz Pharmaceuticals Analyst Rating Update On October 3, 2023, Jazz Pharmaceuticals (JAZZ) received a "Maintains" action from UBS, with analyst Ashwani Verma

Read the full story at gurufocus.com →